Also known as: BPH, benign prostatic hypertrophy, prostatic enlargement, LUTS, lower urinary tract symptoms
Overview
Histologic diagnosis of hyperplasia of prostatic stromal and epithelial cells, typically producing transitional zone enlargement and bladder outlet obstruction with lower urinary tract symptoms (LUTS).
Epidemiology
Histologic BPH present in ~50% of men over 50 and ~80% over 80; ~25-30% experience moderate-to-severe LUTS.
Try two board-style Benign Prostatic Hyperplasia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1RenalEasy
A 55-year-old man with benign prostatic hyperplasia reports urinary frequency, nocturia four times nightly, and a weak stream. He has not tried any medications. Post-void residual volume is 250 mL and the International Prostate Symptom Score is 22 (severe). Which of the following is the most appropriate first-line pharmacotherapy?
AOxybutynin
BTadalafil
CBethanechol
DTamsulosin
EFinasteride
Reveal answer & full explanation
Correct answer: D — Tamsulosin
AOxybutynin
BTadalafil
CBethanechol
DTamsulosin✓
EFinasteride
Why Tamsulosin is correct
Alpha-1 blockers relax prostatic and bladder-neck smooth muscle, giving the most rapid symptom relief (days to weeks) in benign prostatic hyperplasia.
With severe symptoms (IPSS 22) and no prior therapy, an alpha-blocker is appropriate first-line monotherapy per current urologic guidance.
It improves urinary flow without the months-long delay of prostate-shrinking agents.
Why the others are wrong
Tadalafil — a PDE5 inhibitor approved for BPH symptoms regardless of erectile dysfunction, but it carries a weaker (conditional) AUA recommendation than alpha-blockers and does not meaningfully improve peak urinary flow or post-void residual (buzzword trap on 'approved for BPH').
Finasteride — a 5-alpha-reductase inhibitor that shrinks large prostates over 6-12 months; its onset is too slow for prompt relief (right-class, wrong-timing).
Oxybutynin — an anticholinergic for overactive bladder that can precipitate urinary retention given the elevated post-void residual (anchoring on storage symptoms).
Bethanechol — a muscarinic agonist used for urinary retention from an underactive detrusor, so the elevated post-void residual makes it tempting; here the residual reflects prostatic outlet obstruction, which bethanechol does not relieve and which is a contraindication to its use (retention-mechanism trap).
Question 2RenalMedium
A 68-year-old man reports nocturia 3 to 4 times nightly, a weak urinary stream, hesitancy, and a sensation of incomplete emptying for the past year. Digital rectal exam reveals a symmetrically enlarged, firm, smooth, non-tender prostate. PSA is 3.2 ng/mL and urinalysis is unremarkable. Which process best explains his lower urinary tract symptoms?
BNeutrophilic infiltration from acute bacterial infection
CFibrotic stricture narrowing the bulbar segment of the urethra
DPeriurethral stromal and glandular hyperplasia compressing the urethra✓
EAge-related detrusor underactivity with impaired bladder emptying
Why Periurethral stromal and glandular hyperplasia compressing the urethra is correct
This is benign prostatic hyperplasia (BPH)
With aging, dihydrotestosterone (DHT) — formed when 5-alpha-reductase converts testosterone — drives nodular hyperplasia of both stromal smooth muscle and glandular epithelium in the transition zone of the prostate, which surrounds the urethra
This periurethral enlargement mechanically narrows the prostatic urethra and produces obstructive and irritative lower urinary tract symptoms (weak stream, hesitancy, nocturia, incomplete emptying)
The symmetric, smooth, non-tender gland and a PSA that is not elevated for his age fit benign hyperplasia
Why the others are wrong
Neutrophilic infiltration from acute bacterial infection — describes acute bacterial prostatitis, which would present with fever, dysuria, and an exquisitely tender boggy prostate, not a chronically enlarged smooth gland
Malignant glandular proliferation arising peripherally — describes prostate cancer, which originates in the peripheral zone and is typically felt as a hard, asymmetric nodule rather than smooth symmetric enlargement
Fibrotic stricture narrowing the bulbar segment of the urethra — describes urethral stricture disease, which can cause a weak stream and incomplete emptying; it may follow urethral trauma, catheterization or instrumentation, or urethritis but is often idiopathic, and it would not explain the symmetrically enlarged prostate on rectal exam
Age-related detrusor underactivity with impaired bladder emptying — detrusor underactivity becomes more common with age and can also cause a weak stream, hesitancy and incomplete emptying, but it does not enlarge the prostate; the smooth, symmetrically enlarged gland points to outlet obstruction from transition-zone hyperplasia, and detrusor underactivity can be confirmed only by urodynamic pressure-flow studies
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Benign Prostatic Hyperplasia (BPH) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Age-related hormonal changes (rising estrogen-to-testosterone ratio, continued local DHT production via 5-alpha-reductase) drive nodular hyperplasia in the transitional zone, compressing the prostatic urethra. Alpha-1-adrenergic tone in prostatic smooth muscle contributes to dynamic obstruction (vs static obstruction from gland size).
Serum creatinine only if renal impairment, retention, or hydronephrosis is suspected; the routine initial AUA evaluation is history, DRE, symptom score (AUA-SI/IPSS), and urinalysis
PSA — discuss in men with >10-year life expectancy; helps estimate prostate volume and treatment response
Validated symptom score (AUA-SI or IPSS)
Imaging
Post-void residual volume — bedside bladder ultrasound; concerning if >100-150 mL
Renal ultrasound if elevated creatinine, recurrent UTIs, retention, or hematuria
Cystoscopy if hematuria, recurrent UTI, or refractory symptoms
Urodynamics in atypical cases or surgical planning
Transrectal ultrasound — limited role; useful for measuring prostate size before surgery
Reduces risk of acute urinary retention and need for surgery
Reduces PSA by ~50% — multiply measured PSA by 2 for cancer screening interpretation
Side effects: sexual dysfunction (decreased libido, ED, ejaculatory disorders), gynecomastia
Combination therapy
Alpha-blocker + 5-ARI (e.g., tamsulosin + dutasteride) — superior to monotherapy for moderate-to-severe symptoms with prostate enlargement (MTOPS, CombAT trials)
Use for at least 1 year for full benefit
Other pharmacologic options
PDE5 inhibitor — tadalafil 5 mg daily — useful when ED coexists
Anticholinergics or beta-3 agonists (mirabegron) — if overactive bladder symptoms predominate; caution if elevated PVR
Endoscopic: transurethral resection of the prostate (TURP) — historical gold standard; transurethral incision of prostate (TUIP) for small glands
Laser enucleation (HoLEP, ThuLEP) — for very large prostates
Open or robotic simple prostatectomy — for very large (>80-100 g) prostates
Complications
Acute urinary retention (AUR) — sudden inability to void, painful distended bladder; treat with catheter, alpha-blocker; trial of void after 3-7 days
Recurrent UTI
Bladder stones, hematuria
Bladder decompensation, hydronephrosis, postrenal AKI
Surgical complications: bleeding, retrograde ejaculation (~70% after TURP), urinary incontinence, urethral stricture, TUR syndrome (hyponatremia from monopolar irrigation)
PANCE pearls
5-alpha reductase inhibitors reduce serum PSA by ~50%; double the measured PSA when screening men on finasteride/dutasteride.
Alpha-blockers can cause intraoperative floppy iris syndrome — alert ophthalmology before cataract surgery; effect can persist for weeks after discontinuation.
Acute urinary retention is treated with urethral catheterization; drain the bladder completely, since gradual decompression or intermittent clamping has not been shown to reduce hematuria or hypotension. Monitor for post-obstructive diuresis and start an alpha-blocker before a trial without catheter.
Avoid anticholinergics, opioids, decongestants, and antihistamines in BPH patients — can precipitate retention.
Daily tadalafil 5 mg is approved for both BPH and ED — useful when both conditions coexist.
Combination therapy (alpha-blocker + 5-ARI) is best for men with large prostates and bothersome symptoms; expect at least 6-12 months for full effect of 5-ARI.
BPH ≠ prostate cancer — discuss separate cancer screening based on patient preferences and risk.
References
AUA 2026 — Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026), Parts I-III (Goueli R et al., J Urol 2026;216:143-170)
MTOPS — The Long-term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of BPH (McConnell et al., NEJM 2003)
CombAT — Dutasteride plus Tamsulosin Combination Treatment in Men with BPH (Roehrborn et al., Eur Urol 2010)
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.